Drug Trial Radar · NCT06448676
Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
325
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Jan 15, 2027
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Universitair Medical Centrum Groningen
- First posted
- Jun 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study Type: This is a multicenter, triple-blind, randomized controlled trial. Purpose: The goal of this clinical trial is to compare the effectiveness and safety of all commercially available Botulinum Neurotoxin Type A (BoNT-A) products for treating glabellar rhytides, commonly known as frown lines. This study is designed to provide comprehensive data on how these treatments compare in terms of improving frown lines and the duration of their effects. Main Questions the Study Aims to Answer: Which BoNT-A product provides the longest lasting effect on reducing glabellar rhytides? How do these products compare in terms of safety and the occurrence of side effects? Participant Tasks: Women aged 18 years or older with moderate to severe glabellar lines will participate. Participants will receive injections of a BoNT-A product into specific facial muscles. They will need to take weekly photographs using their smartphones to document changes in their frown lines. These photos will be securely sent to our research team for analysis. Participants will complete questionnaires at the start and end of the study to assess their satisfaction, quality of life, and any changes in their condition. Comparison Group: Researchers will compare participants receiving different types of BoNT-A products to see which one is more effective at reducing frown lines and maintaining these effects over time. The safety profiles of these products will also be compared to determine which has the fewest and least severe side effects. This study aims to fill important gaps in our understanding of Botulinum Neurotoxin Type A treatments, guiding more effective clinical decisions and improving patient outcomes.
Conditions
- Wrinkle
- Glabellar Frown Lines
- Glabellar Furrowing
Interventions
Botulinum toxin type ADrug
Head-to-head comparison of all commercially available botulinum neurotoxin type A products
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Clinical EfficacyTime frame: From baseline to week 16
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Faceland
Amsterdam, Netherlands · Recruiting
Faceland
Eindhoven, Netherlands · Recruiting
Faceland
Utrecht, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.